A Phase I Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan in Patients With Advanced or Metastatic Digestive Adenocarcinoma as First- or Second-line Treatment
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Granulocyte colony-stimulating factors
- Indications Adenocarcinoma; Anal cancer; Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms SIRINOX
- Sponsors Nordic Group
- 20 Aug 2019 Status changed from recruiting to completed.
- 05 Jun 2018 Results of S-1 plus irinotecan (n=14), presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 16 Aug 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2020.